Systematic review finds more clinical harm than benefits in Alzheimer’s “treatments” lecanemab, aducanumab, and donanemab

Study ques­tions ben­e­fit of new Alzheimer’s drug (UGA Today): Last sum­mer, the U.S. Food and Drug Admin­is­tra­tion ful­ly approved the first drug shown to slow the progress of Alzheimer’s. But new research from the Uni­ver­si­ty of Geor­gia sug­gests that patients and care­givers may not expe­ri­ence any ben­e­fit from the drug in their dai­ly lives. The drug, Leqembi,…

Read More

Alzheimer’s & Dementia researchers challenge FDA’s approval of Aduhelm given lack of evidence for beta-amyloid as a marker

Doc­tors Blast Bio­gen Alzheimer Approval as ‘Reg­u­la­to­ry Fail­ure’ (Bloomberg): Top researchers who advised the U.S. Food and Drug Admin­is­tra­tion on Bio­gen Inc.’s Alzheimer’s drug blast­ed the agency for approv­ing it, call­ing the deci­sion a “reg­u­la­to­ry fail­ure” that is “at odds with the evidence.”

Read More

Rethinking Alzheimer’s Prevention and Treatment: The Cognitive Shop/ Brain Fitness Center

Edi­tor’s note: Ken­neth S. Kosik, MD, and Ellen Clegg, authors of a recent book on Alzheimer’s Dis­ease pre­ven­tion and treat­ment, force­ful­ly pro­pose a new frame­work and mod­el for brain care: What about set­ting up “cog­ni­tive shops” as “a sort of one-stop shop­ping for every­thing from Alzheimer’s dis­ease pre­ven­tion to guid­ed care for mild or moderate…

Read More